PTC Therapeutics closes acquisition of Sangamo's ST-920 Fabry gene therapy
The one-time AAV gene therapy is headed toward a rolling BLA submission expected to finish in the fourth quarter of 2026.
SEC filing
Latest
5 stories
Monday, September 21
Friday, August 28
PTC Therapeutics details terms of Sangamo gene therapy asset deal
PTC will pay Sangamo $111 million at closing and could owe up to $100 million more tied to FDA approval milestones for ST-920.
SEC filing
Friday, August 21
PTC Therapeutics registers Phase 2A trial of PTC844 in rheumatoid arthritis
Thursday, August 13
PTC Therapeutics wins bankruptcy auction for Sangamo's Fabry gene therapy ST-920
PTC agreed to pay $111 million upfront plus up to $100 million in milestones for the BLA-stage AAV gene therapy, with a rolling FDA submission targeted for the fourth quarter of 2026.
SEC filing
Thursday, July 30
PTC Therapeutics reports Q2 2026 revenue of $361 million, raises full-year guidance
Sephience sales drove product revenue growth as the company reported net income and advanced its Huntington's disease and Friedreich's ataxia programs.
SEC filing